Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Price

AMRXStock

$19.18+94.33%52W

Market Cap$6.68B

P/E85.00x

PEG Ratio1.83

Div yield—

Beta1.23

AMRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)36.28%

Price vs S&P 500 (4W)-3.54%

PEG Ratio1.83

VGM Score60.68

P/E Ratio (Annual)85.00x

P/CF (Annual)18.02x

Book Value / Share (Quarterly)$0.10

P/TBV (Annual)285.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.92%

Cash Flow / Share (Quarterly)$-0.04

Price vs S&P 500 (YTD)40.30%

Gross Margin (TTM)39.32%

Net Profit Margin (TTM)5.05%

EPS (TTM)$0.48

10-Day Avg Trading Volume3.79M

EPS Excl Extra (TTM)$0.48

Revenue Growth (5Y)8.66%

EPS (Annual)$0.22

ROI (Annual)-3.09%

Gross Margin (Annual)36.88%

Net Profit Margin (5Y Avg)-2.13%

Cash / Share (Quarterly)$0.40

P/E Basic Excl Extra (TTM)38.92x

Revenue Growth QoQ (YoY)9.89%

EPS Growth (5Y)-18.37%

P/E Normalized (Annual)85.00x

ROA (Last FY)1.96%

Revenue Growth TTM (YoY)9.28%

EBITD / Share (TTM)$1.98

ROE (5Y Avg)-118.23%

Operating Margin (TTM)14.56%

Cash Flow / Share (Annual)$0.72

P/B Ratio185.48x

P/B Ratio (Quarterly)167.38x

Net Income / Employee (Annual)$8,500

EV / Revenue (TTM)2.80x

Net Interest Coverage (TTM)1.60x

ROA (TTM)4.31%

EPS Growth QoQ (YoY)152.81%

EV / EBITDA (TTM)13.46x

EPS Incl Extra (Annual)$0.22

Current Ratio (Annual)2.17x

Quick Ratio (Quarterly)1.38x

3-Month Avg Trading Volume2.42M

52-Week Price Return94.33%

EV / Free Cash Flow (Annual)38.67x

P/E Incl Extra (TTM)38.92x

Revenue / Employee (TTM)$366,800

Tangible BV / Share (Quarterly)$0.05

P/S Ratio (Annual)2.03x

Asset Turnover (Annual)0.82x

52-Week High$21.18

Operating Margin (5Y Avg)6.70%

EPS Excl Extra (Annual)$0.22

CapEx CAGR (5Y)11.55%

Tangible BV CAGR (5Y)-64.27%

26-Week Price Return46.19%

Quick Ratio (Annual)1.42x

13-Week Price Return7.45%

Total Debt / Equity (Annual)136.58x

Current Ratio (Quarterly)2.20x

Enterprise Value$8.73B

Revenue / Share Growth (5Y)-7.03%

Asset Turnover (TTM)0.85x

Book Value / Share Growth (5Y)-51.99%

Revenue / Employee (Annual)$355,100

Inventory Turnover (Annual)3.13x

Pretax Margin (Annual)4.61%

Cash / Share (Annual)$0.90

3-Month Return Std Dev39.12%

Gross Margin (5Y Avg)36.59%

Net Income / Employee (TTM)$18,500

EBITDA CAGR (5Y)13.59%

EBITDA Interim CAGR (5Y)7.51%

ROE (Last FY)-424.61%

Net Interest Coverage (Annual)1.83x

EPS Basic Excl Extra (Annual)$0.22

P/FCF (TTM)25.89x

Receivables Turnover (TTM)3.36x

EV / Free Cash Flow (TTM)18.30x

Total Debt / Equity (Quarterly)82.62x

EPS Incl Extra (TTM)$0.48

Receivables Turnover (Annual)3.61x

ROI (TTM)2.09%

P/S Ratio (TTM)1.96x

Pretax Margin (5Y Avg)-1.75%

Revenue / Share (Annual)$9.29

Tangible BV / Share (Annual)$0.05

Forward P/E16.99x

Free OCF CAGR (5Y)-6.32%

Price vs S&P 500 (52W)78.79%

P/E Ratio (TTM)38.92x

EPS Growth TTM (YoY)7506.35%

Year-to-Date Return52.22%

5-Day Price Return-4.24%

EPS Normalized (Annual)$0.22

ROA (5Y Avg)-1.39%

Net Profit Margin (Annual)2.39%

Month-to-Date Return-4.77%

Cash Flow / Share (TTM)$1.76

EBITD / Share (Annual)$1.90

Operating Margin (Annual)13.05%

LT Debt / Equity (Annual)122.72x

P/CF (TTM)30.51x

ROI (5Y Avg)-3.29%

P/E Excl Extra (TTM)38.92x

LT Debt / Equity (Quarterly)77.65x

EPS Basic Excl Extra (TTM)$0.48

P/TBV (Quarterly)285.99x

P/B Ratio (Annual)140.74x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)6.45%

Book Value / Share (Annual)$0.04

Price vs S&P 500 (13W)4.77%

Net Margin Growth (5Y)-12.16%

Beta1.23x

P/FCF (Annual)27.15x

Revenue / Share (TTM)$9.50

ROE (TTM)174.61%

52-Week Low$9.75

vGradeD

gGradeC

mGradeA

vgmGradeB

AMRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	$0.23	$0.30	+30.28%(+$0.07)
Q1 2026	May 7, 2026	$0.17	$0.27	+59.62%(+$0.10)
Q4 2025	Feb 27, 2026	$0.18	$0.21	+14.07%(+$0.03)
Q3 2025	Oct 30, 2025	$0.14	$0.17	+22.89%(+$0.03)
Q2 2025	Aug 5, 2025	$0.17	$0.25	+42.95%(+$0.08)

AMRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.09

4.10

4.18

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals develops and manufactures pharmaceutical products across three segments: Affordable Medicines (generics and essential drugs), Specialty (branded pharmaceuticals for CNS and endocrine disorders), and AvKARE (government pharmaceutical distribution). Operating in the U.S., India, and Ireland, the company serves diverse market segments including cost-conscious patients, specialty therapy areas, and government agencies.

AMRX Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.23

Revenue estimate$812.11M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AMRX Insider Transactions

SellAug 13, 2026
KIELY JOHN J.
Director
Shares: 50,000Value: $882,000
SellAug 12, 2026
DALY JASON B.
Officer
Shares: 216,613Value: $3.77M
SellAug 12, 2026
SHAH NIKITA
Officer
Shares: 146,403Value: $2.56M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

AXTAAxalta Coating Systems Ltd.Paints & Coatings
EMNEastman Chemical CompanyPlastics & Resins
HXLHexcel CorporationPlastics & Resins
ELFe.l.f. Beauty, Inc.Cosmetics & Toiletries
LNTHLantheus Holdings, IncIn Vitro Diagnostics
ICLICL Group Ltd.Agricultural Chemicals
IOVAIovance Biotherapeutics, Inc. Common StockBiological Products
MOSThe Mosaic CompanyAgricultural Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

52-Week Range

Low$9.75

High$21.18